SEMINAR: �Signalling pathways intersected by the Src family tyrosine kinase Lyn involved in blood development and cancer�

Associate Professor Evan Ingley heads the Cell Signalling group at WAIMR, which has an interest in understanding the signalling networks or "information highways" of both normal and diseased cells. Many of the new generation anti-cancer drugs disrupt these signalling networks and bring about a "normalization" of protein interactions/pathways. One of the underlying control mechanisms of these processes is that of regulated protein-protein interactions through post-translational modifications such as phosphorylation. A/Prof Ingley's group focuses on an enzyme, Lyn, which modifies proteins via specific phosphorylation on tyrosine residues and through this process mediates specific protein interactions that can enhance or hinder particular cellular processes including cell growth, shape, movement, differentiation and death. Currently his research group is analysing the biological and signalling consequences of mice expressing mutants of Lyn that either inhibit its activity of enhance its activity; how the Lyn substrate Csk binding protein (Cbp) can be used to disrupt Lyn signals in cancer cells; delineating a novel Lyn signalling pathway mediated by AFAP1L1 that controls cancer cell invasion/metastasis; and the novel molecule Liar, which regulates nuclear/cytoplasmic shuttling.